Session 101 - 12th CROI

Home

Session 101 Poster Abstracts
Antiretroviral Therapy: Regimens, Predictors of Response, and Clinical Outcomes
Thursday, 1:30 - 3:30 pm
Hall A

586	An Updated Meta-analysis of Triple Combination Therapy in Antiretroviral-naive HIV-infected Adults John Bartlett*¹, M Fath², R DeMasi³, J Quinn⁴, A Hermes², and F Rousseau⁴ ¹Duke Univ, Durham, NC, USA; ²Abbott Labs, Abbott Park, IL, USA; ³Trimeris, Inc, Durham, NC, USA; and ⁴Gilead Sci, Foster City, CA, USA
587	A Randomized Comparison between Abacavir and Stavudine, both Combined with Lamivudine/Efavirenz, in Antiretroviral-Naive Patients. Final 96-Week Results of the ABCDE Study Daniel Podzamczer*¹, E Ferrer¹, P Sanchez¹, J Gatell², M Crespo³, M Lonca², J Sanz⁴, J Niubo⁵, S Veloso⁶, J Llibre⁷, P Barrufet⁸, M Ribas⁹, E Merino¹⁰, J Martínez-Lacasa¹¹, C Alonso-Villaverde¹², and ABCDE Study Group ¹Hosp Univ de Bellvitge, Barcelona, Spain; ²Hosp Clin, Barcelona, Spain; ³Hosp Vall d'Hebron, Barcelona, Spain; ⁴Hosp Principe de Asturias, Madrid, Spain; ⁵Hosp Univ de Bellvitge, Barcelona, Spain; ⁶Hosp Joan XXIII, Tarragona, Spain; ⁷Hosp de Calella, Barcelona, Spain; ⁸Hosp de Mataro, Barcelona, Spain; ⁹Hosp Son Dureta, Palm de Mallorca, Spain; ¹⁰Hosp Gral de Alilcante, Spain; ¹¹Hosp Mutua de Terrassa, Barcelona, Spain; and ¹²Hosp St Joan de Reus, Spain
588	No Evidence for Poor Immunologic Response in Patients Treated with a Combination of Tenofovir and Didanosine at 250 mg Daily Urs Karrer*¹, B Ledergerber¹, R Weber¹, H J Furrer², L Elzi³, M Battegay³, R Speck¹, and the Swiss HIV Cohort study (SHCS) ¹Zurich Univ Hosp, Switzerland; ²Berne Univ Hosp, Switzerland; and ³Basel Univ Hosp, Switzerland
589	Baseline CD4 Percentage Is Predictive of Survival in Patients Starting Antiretroviral Therapy, including Those with CD4 Cell Counts Between 200 and 350 cells/ mL David Moore*¹, R Hogg², B Yip¹, E Wood², K Craib¹, R Harrigan², and J Montaner² ¹British Columbia Ctr for Excellence in HIV/AIDS, Vancouver, Canada and ²British Columbia Ctr for Excellence in HIV/AIDS, Vancouver, Canada
590	Mortality Rates According to Initial HAART Regimen: A Collaborative Analysis of 12 Prospective Cohort Studies Robert Hogg*¹, J Lundgren², D Costagliola³, A Monforte⁴, B Ledergerber⁵, F de Wolf⁶, G Fusco⁷, S Staszewski⁸, G Chêne⁹, A Phillips¹⁰, J Gill¹¹, J Rockstroh¹², M May¹³, J Sterne¹³, M Egger¹⁴, and ART Cohort Collaboration ¹British Columbia Ctr for Excellence in HIV/AIDS, Vancouver, Canada; ²Eurosida; ³French Hospital Database on HIV; ⁴Italian Cohort of Antiretroviral-Naive Patients; ⁵Swiss HIV Cohort Study; ⁶AIDS Therapy Evaluation Project Netherlands; ⁷GlaxoSmithKline, Research Triangle Park, NC, USA; ⁸Frankfurt HIV Cohort; ⁹Aquitaine Cohort; ¹⁰Royal Free Hosp Cohort, London, UK; ¹¹South Alberta Clin, Calgary, Canada; ¹²Köln/Bonn Cohort; ¹³Univ of Bristol, UK; and ¹⁴ART Cohort Collaboration
591	Long-term Effect of HAART in Preventing AIDS and Death Compared with No Treatment and with Dual Therapy: The Swiss HIV Cohort Study Jonathan Sterne*¹, M Hernan², B Ledergerber³, K Tilling¹, R Weber³, J Robins², M Egger⁴, and the Swiss HIV Cohort Study ¹Bristol, UK; ²Boston, MA, USA; ³Zurich, Switzerland; and ⁴Berne, Switzerland
592	Effect of HAART, CD4 Cell Counts, and Viral Load on Incidence of AIDS-defining Events Isabelle Kousignian*¹, S Abgrall^2,3, S Grabar^2,4, A Mahamat⁵, E Rouveix⁶, E Teicher⁷, D Costagliola¹, and Clinical Epidemiology Group of the French Hospital Database on HIV ¹INSERM EMI 0214, Paris, France; ²INSERM EMI 0214, Paris, France; ³Hosp Avicenne, Bobigny, France; ⁴Hosp Cochin, Paris, France; ⁵Ctr Hosp Univ de Nîmes, France; ⁶Ctr Hosp Univ Ambroise Paré, Boulogne, France; and ⁷Hosp Paul Brousse, Villejuif, France
593	Trends Over Time in Initial Virological Failure of First HAART: 1996 to 2002. A Joint Cohort Analysis of 4143 Subjects Fiona Lampe*¹, J Gatell², S Staszewski³, M Johnson⁴, C Pradier⁵, J Gill⁶, E de Lazzari², B Dauer³, M Youle⁴, E Fontas⁵, H Krentz⁶, and A Phillips¹ ¹Royal Free and Univ Coll Med Sch, London, UK; ²Univ of Barcelona, Spain; ³JW Goethe Univ, Frankfurt, Germany; ⁴Royal Free Hosp, London, UK; ⁵Hosp l'Archet, Nice, France; and ⁶Univ of Calgary, Alberta, Canada
594	Risk and Predictors of Triple-class Antiretroviral Drug Failure in Danish HIV-infected Individuals Nicolai Lohse*^1,2, N Obel^1,2, G Kronborg⁵, A Laursen⁴, C Pedersen^1,2, C Larsen⁶, B Kvinesdal⁷, H Sørensen⁸, and J Gerstoft⁹ ¹Odense Univ Hosp, Denmark; ²Univ of Southern Denmark, Odense; ⁴Århus Univ Hosp, Skejby, Denmark; ⁵Copenhagen Hvidovre Univ Hosp, Denmark; ⁶Aalborg Hosp, Denmark; ⁷Helsingør Hosp, Denmark; ⁸Univ of Arhus, Denmark; and ⁹Copenhagen Univ Hosp, Rigshospitalet, Denmark
595	HIV and Non-HIV-related Deaths and Their Relationship to Immunodeficiency: The D:A:D Study Rainer Weber*¹, N Friis-Møller², C Sabin³, P Reiss⁴, A D'Arminio Monforte⁵, F Dabis⁶, W El-Sadr⁷, S De Wit⁸, L Morfeldt⁹, M Law¹⁰, C Pradier¹¹, G Calvo¹², C Holkmann-Olsen¹³, A Phillips³, J Lundgren², and On behalf of the D:A:D Study Group ¹Zurich Univ Hosp, Switzerland; ²Copenhagen HIV Prgm, Hvidovre Univ Hosp, Denmark; ³Royal Free and Univ Coll, London, UK; ⁴ATHENA Cohort Study Group, HIV Monitoring Fndn, Academic Med Ctr, Univ of Amsterdam, The Netherlands; ⁵L Sacco Hosp, Univ of Milan, Italy; ⁶Aquitaine Cohort, Bordeaux Univ Hosp, INSERM U593, France; ⁷Community Prgms for Clin Res on AIDS, Harlem Hosp, Columbia Univ, New York, NY, USA ; ⁸St-Pierre Cohort, Ctr Hosp Univ St-Pierre, Brussels, Belgium; ⁹HIVUS, Karolinska Hosp, Stockholm, Sweden; ¹⁰Australian HIV Observational Database, Natl Ctr in HIV Epidemiology and Clin Res, Sydney, Australia; ¹¹Ctr Hosp Univ Nice, Hosp de l'Archet, France; ¹²BASS, Autonomous Univ of Barcelona, Spain; and ¹³EuroSIDA, Copenhagen HIV Prgm, Hvidovre Univ Hosp, Denmark
596	Age and Sex Effect on Response to Initial HiAART Kristine Patterson*¹, S Napravnik¹, J Eron¹, J Keruly², and R Moore² ¹Univ of North Carolina at Chapel Hill, USA and ²Johns Hopkins Univ, Baltimore, MD, USA
597	HIV Gender Differences in Morbidity and Mortality and the Effect of Aging Sonya Hadrigan*, M Miguez-Burbano, X Burbano, A Rodriguez, J Jackson Jr, and G Shor-Posner Univ of Miami, FL, USA
598	HIV-1 Subtypes and Virological Response to HAART in Europe Wendy Bannister*¹, L Ruiz², C Loveday³, S Vella⁴, K Zilmer⁵, D Podlekareva⁶, B Knysz⁷, A Phillips¹, J Lundgren⁶, A Mocroft¹, and the EuroSIDA study group ¹Royal Free and Univ Coll Med Sch, London, UK; ²Hosp Univ (UAB), Badalona, Spain; ³Intl Clin Virology Ctr, Buckinghamshire, UK; ⁴Inst Superiore di Sanita, Rome, Italy; ⁵Tallinn Merimetsa Hosp, Estonia; ⁶Copenhagen HIV Prgm, Hvidovre Univ Hosp, Denmark; and ⁷Med Univ, Wroclaw, Poland
599	Early Virologic Response at 1-Month and 8-Month Median Follow-up of a New Triple NUC Combination (Zidovudine, Lamivudine, and Tenofovir) in 36 Antiretroviral-naive, HIV-1-infected Patients David Rey*, M Krebs, M Partisani, G Hess-Kempf, C Cheneau, M Priester, C Bernard-Henry, E de Mautort, and J M Lang Hosp Univ, Strasbourg, France
600	Predictors of Virological Failure at 6 Months of Therapy in HIV-1-infected Patients Starting HAART in Porto Alegre, Brazil S Tuboi¹, Eduardo Sprinz*², L Harrison³, R Albernaz¹, and M Schechter⁴ ¹Fogarty AIDS Intl Training and Res Prgm, Univ of Pittsburgh, PA, USA; ²Hosp de Clinicas de Porto Alegre, Univ Federal do Rio Grande do Sul, Brazil; ³Univ of Pittsburgh, PA, USA; and ⁴Univ Hosp Clementino Fraga Son, Federal Univ of Rio de Janeiro, Brazil
601a	Risk of AIDS and Death at Given HIV RNA and CD4 Count Levels, according to Specific Antiretroviral Drugs in the CART Regimen Christian Holkmann-Olsen*¹, J Gatell², B Ledergerber³, C Katlama⁴, N Friis-Møller¹, J Weber⁵, A Horban⁶, S Staszewski⁷, J Lundgren¹, A Phillips⁸, and EuroSIDA ¹Copenhagen HIV Prgm, Hvidovre Univ Hosp, Denmark; ²Hosp Clin, Barcelona, Spain; ³Zurich Univ Hosp, Switzerland; ⁴Hosp Pitie-Salpetriere, Paris, France; ⁵St Mary's Hosp, London, UK; ⁶Wojewodzki Szpital Zakazny, Warsaw, Poland; ⁷JW Goethe Univ Hosp, Frankfurt, Germany; and ⁸Royal Free and Univ Coll Med Sch, London, UK
601b	A Comparison of 6 Antiviral Regimens in Drug-naive Patients Giuliano Rizzardini*¹, D Trabattoni², A Capetti³, M Migliorino¹, G Vigevani³, and M Clerici² ¹Hosp di Circolo, Busto Arsizio, Italy; ²Univ of Milan, Italy; and ³Hosp Luigi Sacco, Milan, Italy